Authors urge acceleration of herpes simplex virus vaccination efforts
THURSDAY, July 18, 2024 (HealthDay News) — Herpes simplex virus (HSV)-2 and HSV-1 infections and their consequences cost $35 billion globally in 2016, according to a study published online July 2 in BMC Global and Public Health.
Nathorn Chaiyakunapruk, Pharm.D., Ph.D., from the University of Utah in Salt Lake City, and colleagues estimated the global economic impact of genital HSV-2 and HSV-1 infections. Disease burden was based on previously published global disease burden studies in 2016 for 194 countries, while estimates of health care resource utilization were sourced from a literature review and online interviews with 20 experts from all six World Health Organization regions.
The researchers found that genital HSV-2 ($31.2 billion) and HSV-1 ($4.0 billion) infections and their consequences were costly globally. The greatest economic burden emanated from the combined Americas and Western Pacific regions, which accounted for almost two-thirds of the global burden ($20.8 billion). A large proportion of the economic burden was borne by high- and upper middle-income countries (76.6 percent or $27.0 billion). HSV-2 recurrence drove costs.
“HSV prevention interventions have the potential to avert a large economic burden in addition to disease burden; thus, efforts to accelerate HSV vaccine development are crucial,” the authors write.
Cancer-Attributable Costs High for Seniors, Vary With Cancer Phase, Type, Race 
RYGB, Sleeve Gastrectomy Cost-Effective for Teens With Severe Obesity 
2026 Costs of Dementia Care Expected to Be $818 Billion in the United States 
Telemedicine Visits Cost Less Than In-Person Visits 
One-Third of Patients With Chronic Rhinosinusitis With Nasal Polyps Exhibit Anxiety Symptoms 
Children, Teens Have Higher Psychological Burden of Atopic Dermatitis 
Social Prescribing Aids Teens Waiting for Mental Health Services 
Sense of Smell Linked to Mental Health 
